Above expectations

Teva Reports Revenue of $4.4 Billion

Adjusted gross profit margin soared to a decade high of 58.7% • The company raised its annual revenue forecast following sharp growth in innovative medicines

Teva stock
Teva stock | Photo: Shutterstock

Teva Pharmaceutical Industries (TEVA) today, Tuesday, reported its financial results for the third quarter of 2026, showing continued acceleration in the company’s transformation strategy toward innovative medicines.

Teva logistics center
Teva logistics center | Photo: Yossi Aloni, Flash90

Despite a moderate decline of about 2% in total revenue, which amounted to $4.4 billion as a result of intensifying generic competition in the US market, the company posted a marked improvement in operating and gross profitability and announced that it was raising its full-year revenue forecast for its main growth drivers.

Surge in innovative medicines offsets erosion in generics

In the third quarter of the year, Teva’s three leading innovative brands — Austedo, Ajovy and Uzedy — generated combined revenue of about $1.1 billion, reflecting an impressive 33% increase compared with the corresponding period last year in local currency terms.

Flagship drug Austedo posted global revenue of $751 million and growth of 21%. Migraine treatment Ajovy grew by 61% to revenue of $269 million, while Uzedy nearly doubled its sales, rising 96% to a total of $85 million.

Teva’s logistics center in Shoham. Photo: Sivan Farag
Teva’s logistics center in Shoham | Photo: SIVANFARAG

The rapid growth of the innovative product portfolio largely offset a decline of about 16% in global generic revenue, stemming mainly from the entry of additional competitors for the generic version of Revlimid (lenalidomide) in the United States.

At the same time, Teva’s biosimilars business continues to expand and is expected to surpass $800 million in revenue this year, a target achieved one year ahead of the original 2027 target plan.

Surge in profitability margins and record adjusted earnings

The shift in the sales mix toward innovative, high-margin products led to a significant improvement in profitability metrics.

The adjusted gross profit margin (non-GAAP) climbed to 58.7% from 55.3% in the corresponding quarter, the highest quarterly level recorded by Teva in the past decade, excluding one-time milestone payments. The GAAP gross profit margin stood at 55.5%, compared with 51.4% last year.

EBITDA
EBITDA | Photo: Shutterstock

Adjusted operating profit totaled $1.39 billion, representing an operating margin of 31.7%, while adjusted EBITDA reached $1.5 billion, an increase of 7% compared with the corresponding quarter.

On the bottom line, adjusted earnings per share stood at $0.86, an increase of 10%. Under generally accepted accounting principles (GAAP), Teva posted net income of $233 million and diluted earnings per share of $0.20, a decline mainly affected by provisions for asset impairments, legal settlements and financing expenses related to the early repayment of debt.

The company generated free cash flow of $495 million during the quarter.

2026 forecast raised

Teva President and CEO Richard Francis said the quarterly performance demonstrates the implementation of the Pivot to Growth strategy and the financial transformation the company is undergoing.

Alongside the results, Teva recorded a series of strategic achievements, led by FDA approval and the launch of the schizophrenia treatment Weltruza, which, together with Uzedy, establishes a portfolio of long-acting treatments with peak sales potential of $1.5 billion to $2 billion.

Richard Francis, president and CEO of Teva
Richard Francis, president and CEO of Teva | Photo: Elad Malka, Yossi Aloni, Flash90

Teva also signed an expansion of its biosimilars collaboration with Samsung Bioepis and acquired the drug BXCL-501. On the financial front, the company completed a debt refinancing of about $4.9 billion, received a credit rating upgrade back to investment grade and completed a direct listing of its shares for trading on the New York Stock Exchange.

Following the positive momentum, the company’s management raised its annual revenue forecast to a range of $16.7 billion to $17.0 billion, compared with $16.5 billion to $16.85 billion previously.

Sales forecasts for all innovative products were revised upward: Austedo sales in 2026 are expected to reach $2.55 billion to $2.65 billion, Ajovy sales are expected to reach $930 million to $960 million, and Uzedy sales are expected to reach $290 million to $310 million. The annual free cash flow forecast was raised to a range of $2.1 billion to $2.4 billion, while the adjusted earnings-per-share forecast was set at $1.92 to $2.11.

Key takeaways

  • Teva reported third-quarter 2026 revenue of $4.4 billion, down about 2% year over year, but said profitability improved significantly.
  • Revenue from Teva’s three leading innovative brands — Austedo, Ajovy and Uzedy — totaled about $1.1 billion, up 33% in local currency terms.
  • Adjusted gross profit margin rose to 58.7%, the highest quarterly level Teva has recorded in the past decade excluding one-time milestone payments.
  • Teva raised its full-year revenue forecast to $16.7 billion to $17.0 billion and increased guidance for Austedo, Ajovy and Uzedy sales.
  • The company also lifted its annual free cash flow forecast to $2.1 billion to $2.4 billion and its adjusted EPS forecast to $1.92 to $2.11.

Questions and answers

Why did Teva’s revenue decline while results improved?
Total revenue fell about 2% because of stronger generic competition in the US market, especially in generic Revlimid. However, growth in innovative medicines and better margins offset much of that pressure.
Which Teva drugs drove growth in the quarter?
Austedo, Ajovy and Uzedy were the main growth drivers, generating about $1.1 billion combined. Austedo brought in $751 million, Ajovy $269 million and Uzedy $85 million.
What guidance did Teva raise for 2026?
Teva raised its full-year revenue forecast to $16.7 billion to $17.0 billion, up from $16.5 billion to $16.85 billion. It also lifted its free cash flow and adjusted EPS guidance and increased outlooks for all three innovative products.

Share this story

About the writer

Shai Nogai

Writes for TV10, Israel’s economic channel. This story was translated from the original Hebrew.

More stories by Shai Nogai

More for you